Most of these vaccines are being tested in breast and gastric cancers, but as their efficacy is demonstrated, it is expected that they will be tested in a wide range of HER2-positive solid tumors, as is the case with T-DXd. The gene discussed is ERBB2; the disease is gastric cancer.